CYBN קפיטליזציה חשבונאית Cybin Inc

Cybin Inc. (CYBN) is developing advanced antidepressants leveraging unique patents for the delivery of modified psilocybin. This biopharma company is implementing breakthrough therapies for anxiety disorders, opening new horizons in psychiatry. This chart on the GURU.Markets platform captured the 0.27 metric. The firm's environmental policy is limited to laboratory safety controls and the digitalization of documentation during clinical trials.

This metric is calculated as the difference between the issuer's total assets and all liabilities. This figure determines the actual value of net equity available to shareholders after all debts are fully settled. For Cybin Inc. (CYBN), this resource is critical for diversifying the development of psychedelic drugs for psychiatry. By analyzing the equity volume on the balance sheet, an investor assesses the financial stability of the biotech startup. This chart's dynamics allow for a balance between fundamental risks and growth potential.